Sign in
WithdrawnPhase 2

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

Key facts

Who runs it
John M. Buatti
Where
Iowa City, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
15 May 2019
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • External beam radiation therapy
Record updated
9 September 2020
Why it stopped
Not funded

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Ability to understand and willingness to provide informed consent
  • Newly diagnosed, histologically-confirmed supratentorial WHO grade IV gliomas including glioblastoma (all variants) and gliosarcoma
  • Patients must be 18 years of age or older.≥
  • Karnofsky performance status ≥ 70
  • Minimal life expectancy of 12 weeks
  • Maximal contiguous volume of tumor based on high b-value diffusion MRI and perfusion MRI < 1/3 volume of brain
  • Patients must be treated within 6 weeks of most recent resection; Within 21 days of radiation fraction 1, the following blood test parameters must be met:
  • Hemoglobin ≥ 10 g/dL (transfusion is acceptable)
  • absolute neutrophils ≥ 1500/mm3
  • platelet count ≥ 100,000/mm3
  • total bilirubin ≤ 2 x upper limit of normal (ULN) (unless elevated bilirubin is related to Gilbert syndrome)
  • ALT and AST ≤ 5 x ULN
  • serum creatinine ≤ 2.0 mg/dL

Who cannot take part

  • Recurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible
  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is >3 years
  • Evidence of severe concurrent disease requiring treatment
  • Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap
  • Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects
  • Nursing mothers declining to discontinue breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide
  • Evidence of CSF dissemination (positive CSF cytology for malignancy or MRI findings consistent with CSF dissemination)
  • Multifocal disease (>1 lobe of involvement) of discontiguous, contrast enhancing disease as seen on conventional MRI
  • Known active malignancy as determined by treating medical and radiation oncologist
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring inpatient hospitalization or delay treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or compromise subject safety
  • Patients unable to undergo MRI exams
  • Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study

Where in United States

  • University of Iowa Department of Radiation OncologyIowa City, United States

About the trial

What the trial wants to find out

This clinical trial increases radiation to areas of the brain considered to be at risk for cancer. The at-risk areas are identified by a biological MRI scan. The study will look at side effects of the radiation and overall survival.

The group in the trial

  • Radiation TherapyTreatment being tested

    External beam radiation therapy delivered to target volume.

    Treatment: External beam radiation therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma
Record updated
9 September 2020